Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
Earnings call · FY2026 Q3
Executive readout · one minute
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
Forward guidance
5 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
From the 8-K filed Aug 4, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Adjusted EBITDA
fourth quarter fiscal 2026
|
$20M – $23M | Non-GAAP | |
|
Total reported revenue from continuing operations
fiscal year ending September 30, 2026
|
$613M – $618M | GAAP | |
|
Organic revenue for Multiomics
fiscal 2026
|
-1% – 0% | — | |
|
Free cash flow
fiscal 2026
|
10% – 15% | Non-GAAP | |
|
Adjusted EBITDA
fiscal 2026
|
$59M – $62M | Non-GAAP |
How the reported period landed and where the business moved.
SEC filing · Item 2.02
Filed Aug 4, 2026 · complete as-filed document
SEC periodic report
Filed Aug 6, 2026 · complete as-filed document